Noregyna indications
Noregyna Tablets, USP
Noregyna tablets, USP are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Noregyna tablets, USP are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.
Uses of Noregyna in details
Noregyna is a man-made form of progesterone, a naturally occurring female sex hormone. It has a number of uses:
- Low-strength progesterone is used in oral contraceptive pill to prevent pregnancy.
- Medium-strength progesterone is used, to treat irregular, painful or heavy periods, to treat endometriosis (where tissue from the lining of the womb is present in places where it is not normally found), to treat premenstrual syndrome (also known as premenstrual tension, PMS or PMT), to delay periods.
Noregyna description
Noregyna (INN, BAN), also known as Norethindrone (USAN), is a synthetic progestational hormone with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for contraception.
Noregyna dosage
Noregyna Tablets
Therapy with Noregyna tablets must be adapted to the specific indications and therapeutic response of the individual patient.
Secondary Amenorrhea, Abnormal Uterine Bleeding due to Hormonal Imbalance in the Absence of Organic Pathology
2.5 to 10 mg Noregyna tablets may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen.
Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing Noregyna tablets therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with Noregyna tablets.
Endometriosis
Initial daily dosage of 5 mg Noregyna tablets for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of Noregyna tablets is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination.
Noregyna interactions
If a woman on Noregyna takes a drug or herbal product that induces an enzyme(s) that metabolizes Noregyna, particularly CYP3A4, the patient should be counseled to use additional contraception or a different method of contraception. Drugs or herbal products that induce such enzymes may decrease the plasma concentrations of Noregyna and may decrease the effectiveness of Noregyna or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include: Some anti-epileptics (eg, carbamazepine, phenytoin), (fos)aprepitant, barbiturates, bosentan, griseofulvin, some (combinations of) HIV protease inhibitors (eg, nelfinavir, some ritonavir-boosted protease inhibitors), some non-nucleoside reverse transcriptase inhibitors (eg, nevirapine), rifampin and rifabutin, St. John's Wort.
In vitro studies suggest that activated charcoal binds to Noregyna, however the therapeutic effect of Noregyna is not affected when activated charcoal is administered 3 hrs after the previous dose or 12 hrs before the next dose.
Physicians are advised to consult the labeling of concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations and the possible need to adjust dosages.
Laboratory Tests: Certain endocrine and liver function tests and blood components may be affected by progestin-only oral contraceptive use: Sex hormone-binding globulin concentrations may be decreased; thyroxine concentrations may be decreased, due to a decrease in thyroxine binding globulin. Incompatibilities:
Noregyna side effects
Throughout this section, adverse reactions are presented. Adverse reactions are adverse events that were considered to be reasonably associated with the use of Noregyna based on the comprehensive assessment of the available adverse event information. A causal relationship with Noregyna usually cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Clinical Trial Data: The safety of Noregyna was evaluated in 3099 subjects in 2 clinical trials. Of these, 2925 subjects participated in a clinical trial of Noregyna 0.35 mg administered daily and 174 subjects participated in a clinical trial of Noregyna 0.35 mg/day administered on 21 days/cycle. Adverse reactions reported for ≥1% of Noregyna-treated subjects are shown in the table.
Adverse reactions reported by <1% of Noregyna-treated subjects (N=3099) in the previously stated clinical trials are as follows: Psychiatric Disorders: Depression, nervousness. Gastrointestinal Disorders: Gastrointestinal disorder. Skin and Subcutaneous Tissue Disorders: Acne, hirsutism. Musculoskeletal and Connective Tissue Disorders: Pain in extremity. Reproductive System and Breast Disorders: Genital discharge. General Disorders and Administration Site Conditions: Edema.
Post-Marketing Data: Adverse reactions 1st identified during post-marketing experience with Noregyna are included as follows. The frequencies are provided according to the following convention: Very common ≥1/10; common ≥1/100 and <1/10; uncommon ≥1/1000 and <1/100; rare ≥1/10,000, <1/1000; very rare <1/10,000, including isolated reports; unknown (cannot be estimated from the available data).
Adverse reactions are presented by frequency category based on spontaneous reporting rates.
Immune System Disorders: Very rare: Anaphylactic/anaphylactoid reaction, hypersensitivity.
Gastrointestinal Disorders: Very rare: Abdominal pain.
Hepatobiliary Disorders: Very rare: Hepatitis, cholestatic jaundice.
Skin and Subcutaneous Tissue Disorders: Very rare: Alopecia, rash, pruritic rash.
Pregnancy, Puerperium and Perinatal Conditions: Very rare: Ectopic pregnancy.
Reproductive System and Breast Disorders: Very rare: Breast pain, delayed menstruation, irregular menstruation, ovarian cyst, suppressed lactation, vaginal hemorrhage, menorrhagia, withdrawal bleeding when Noregyna is stopped.
Noregyna contraindications
Hypersensitivity to any component of Noregyna. Known or suspected carcinoma of the breast; benign or malignant liver tumor; acute or chronic hepatocellular disease with abnormal liver function; undiagnosed abnormal genital bleeding.
Use in pregnancy: Noregyna is contraindicated during pregnancy.
Many studies have found no effects on fetal development associated with long-term use of contraceptive doses of oral progestins. The few studies of infant growth and development that have been conducted have not demonstrated significant adverse effects. Suspected pregnancy should be ruled out before initiating any hormonal contraceptive use.
Active ingredient matches for Noregyna:
Norethisterone in Brazil.
Estradiol valerate/Norethisterone enantate in Brazil.
List of Noregyna substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Nordron (Taiwan) | |
| Nordron 5 mg | |
| Norelut (Indonesia) | |
| Norelut 5 mg x 5 x 10's (Dexa Medica) | $ 19.53 |
| Noret (Argentina) | |
| Noreta HRT (India) | |
| Noreta HRT 1mg TAB / 10 (German Remedies (Zydus Cadila Healthcare Ltd.)) | $ 0.17 |
| 1 mg x 10's (German Remedies (Zydus Cadila Healthcare Ltd.)) | $ 0.17 |
| Noreta HRT 1 mg Tablet (German Remedies (Zydus Cadila Healthcare Ltd.)) | $ 0.01 |
| NORETA-HRT (India) | |
| NORETA-HRT tab 1 mg x 10's (Zydus (G.Rem)) | $ 0.17 |
| Noreth | |
| Noreth 5 mg Tablet (Taurus Laboratories Pvt. Ltd.) | $ 0.04 |
| NORETHEA | |
| NORETHEA TABLET 1 strip / 10 tablets each (Orchid Chemicals & Pharmaceuticals Ltd) | $ 0.59 |
| Norethindrone Acetate | |
| Norethindrone Acetate tablet 5 mg/1 (Av Pak (US)) | |
| Norethindrone Acetate Barr (United States) | |
| Norethindrone Lupin (United States) | |
| Norethisteron Jenapharm (Germany) | |
| Norethisteron Slovakofarma (Czech Republic) | |
| Norethisteron Zentiva (Czech Republic, Slovakia) | |
| Norethisterone (Argentina, Austria, Belgium, Bulgaria, Canada, Chile, China, Croatia (Hrvatska), Czech Republic, Denmark, Estonia, Finland, France, Germany, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Malaysia, Malta, Netherlands, Norway, Oman, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey) | |
| Tablet; Oral; Norethindrone 5 mg (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | |
| 5 mg x 10's (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.48 |
| Norethisterone 5 mg Tablet (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.05 |
| Norethisterone 5mg TAB / 10 (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.48 |
| NORETHISTERONE / ATOZ tab 5 mg x 10's (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 0.48 |
| Ovcon-35 / 28 28 0.4-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 89.09 |
| Ovcon-50 28 50-1 mcg-mg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 89.09 |
| Loestrin 1.5/30 / 21 21 1.5-30 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 79.32 |
| Loestrin 1/20 / 21 21 1-20 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 79.32 |
| Loestrin Fe 1/20 28 1-20 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 79.32 |
| Loestrin Fe 1.5/30 28 1.5-30 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 77.10 |
| Loestrin 24 Fe 28 1-20 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 75.15 |
| Nor-QD 28 0.35 mg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 65.87 |
| Tri-Norinyl / 28 28 0.5/1/0.5-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 62.63 |
| Ortho-Novum 10/11 / 28 28 35 mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 60.25 |
| Modicon / 28 28 0.5-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 59.99 |
| Norinyl 1+35 / 28 28 1-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 55.99 |
| Ortho-Novum 1/35 / 28 28 1-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 55.99 |
| Brevicon / 28 28 0.5-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 53.00 |
| Norinyl 1+50 / 28 28 1-50 mg-mcg tablet 1 Disp Pack = 28 Pills (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 52.99 |
| Necon 10/11 / 28 28 35 mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 35.99 |
| Ortho-Novum 7/7/7 / 28 28 0.5/0.75/1-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 33.99 |
| Necon 0.5/35 / 28 28 0.5-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 32.99 |
| Necon 1/35 / 28 28 1-35 mg-mcg tablet Disp Pack (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 31.99 |
| Loestrin fe 1-20 tablet (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 5.23 |
| Loestrin 21 1.5-30 tablet (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 3.66 |
| Loestrin 21 1-20 tablet (Atoz Pharmaceuticals (Zota Healthcare Pvt Ltd)) | $ 3.66 |
See 572 substitutes for Noregyna | |
References
- DailyMed. "ESTRADIOL HEMIHYDRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "estradiol". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "estradiol". http://www.drugbank.ca/drugs/DB00783 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Noregyna are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Noregyna. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
